Title: siRNA Targeting KRAS
Filed: Dec. 4, 2006
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."
Title: RNAi Modulation of RSV and Therapeutic Uses Thereof
Filed: Jan. 6, 2006
Inventor: Rachel Meyers, Alnylam Pharmaceuticals
The invention, the patent's abstract states, is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of [RNAi] agents, as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the … invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels, and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses," the abstract adds.
Title: Lipoplex Formulations for Specific Delivery to Vascular Endothelium
Filed: April 20, 2007 PCT Filed: April 20, 2007
Lead Inventor: Jorg Kaufmann, Silence Therapeutics
The invention, the patent application's abstract states, "is related to a lipid composition contained in and/or containing a carrier comprising at least a … lipid component, at least a … helper lipid, and a shielding compound [that] is optionally removable from the lipid composition under in vivo conditions."
The lipid composition-containing carrier, the abstract notes, has an osmolarity of about 50 to 600 mosmol per kilogram, while the liposomes formed by the lipid component, the helper lipid, and the shielding compound in the carrier have a particle size of about 20 to 200 nanometers.
Title: Methods of Inhibiting Tumor Cell Proliferation with FoxM1 siRNA
Filed: Jan. 6, 2005 PCT Filed: Jan. 6, 2005
Lead Inventor: Robert Costa, University of Illinois
The invention, the patent application's abstract states, comprises "methods for inhibiting tumor cell proliferation by inhibiting Fox M1B — also called Fox M1 — activity in a tumor cell. The invention also provides FoxM1B siRNA molecules and pharmaceutical compositions comprising FoxM1B siRNA molecules [that] … can inhibit FoxM1B activity and can inhibit proliferation of tumor cells. The invention further provides methods for preventing tumor growth, progression, or both in an animal comprising inhibiting FoxM1B activity using siRNA molecules or pharmaceutical compositions comprising FoxM1B siRNA molecules."
Title: Gene Silencing by Systemic RNA Interference
Filed: Feb. 22, 2008
Lead Inventor: Craig Hunter, Harvard University
The invention, the patent application's abstract states, comprises "nucleic acid and protein sequences relating to a gene required for systemic RNAi.
"The SID-1 protein is shown to be required for systemic RNAi," and the application claims "nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the sid-1 gene and protein," according to the abstract. "Also provided are methods for reducing the expression of a target gene in a cell, a population of cells, or an animal."